Mar 4, 2026 04:01PM
Feb 4, 2026 07:31AM
Feb 4, 2026 07:30AM
Dec 29, 2025 04:01PM
Dec 29, 2025 04:01PM
Dec 15, 2025 04:01PM
Dec 15, 2025 04:01PM Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Nov 14, 2025 12:41AM
Nov 14, 2025 12:41AM
Nov 13, 2025 04:07PM
Nov 13, 2025 04:07PM
Nov 4, 2025 07:30AM
Oct 23, 2025 04:01PM
Oct 23, 2025 04:01PM Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
Oct 19, 2025 04:15AM
Oct 19, 2025 04:15AM
Sep 11, 2025 08:18AM
Aug 13, 2025 04:29PM
Aug 13, 2025 04:29PM
Aug 7, 2025 04:05PM
Jul 24, 2025 07:30AM Verastem gets fast track status for pancreatic cancer drug VS-7375
Jul 24, 2025 07:30AM
Jul 11, 2025 04:12PM
Jul 11, 2025 04:12PM
Jul 8, 2025 08:50AM
Jun 30, 2025 04:02PM
Jun 30, 2025 04:02PM
Jun 24, 2025 04:02PM Verastem Oncology (VSTM) Announces First Patient Dosed with VS-7375 in U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
Jun 24, 2025 04:02PM
May 22, 2025 05:07PM
May 22, 2025 05:01PM
May 20, 2025 08:33AM
May 20, 2025 08:30AM
May 13, 2025 04:34PM
May 8, 2025 01:44PM Verastem (VSTM) PT Raised to $19 at Jefferies
May 8, 2025 01:17PM
May 8, 2025 11:47AM
Apr 29, 2025 06:28AM
Apr 23, 2025 04:08PM
Apr 23, 2025 04:05PM
Apr 10, 2025 03:34AM
Mar 25, 2025 04:35PM Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Mar 20, 2025 04:01PM
Feb 20, 2025 04:05PM
Jan 23, 2025 07:31AM
Jan 23, 2025 07:30AM
Jan 15, 2025 07:30AM
Jan 15, 2025 07:30AM
Jan 14, 2025 07:31AM Verastem Oncology (VSTM) Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
Jan 14, 2025 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All